Orchestra BioMed Holdings (OBIO) Financial Statements & Analysis

Orchestra BioMed Holdings (OBIO) Income Statement

Orchestra BioMed Holdings reported revenue of $33.48M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 1169.2% from $2.64M a year earlier. Orchestra BioMed Holdings posted a net loss of $52.95M, compared with a net loss of $61.02M a year earlier. Gross margin was 99.4% and operating margin -154.7%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $88.00K, down 89.5% from the same quarter a year earlier.

Orchestra BioMed Holdings Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Orchestra BioMed Holdings, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Mar 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	33.48	2.64	2.64	2.76	3.53	-0.78	5.70
Cost of Revenue	0.19	0.20	0.20	0.19	0.32	0.20	0.15
Gross Profit	33.29	2.43	2.43	2.57	3.21	-0.98	5.56
Operating Expenses
Research & Development	58.19	42.80	42.80	33.82	21.95	12.89	13.48
Selling, General & Administrative	26.91	23.93	23.93	20.26	13.92	7.93	10.83
Operating Expenses	85.10	66.74	66.74	54.08	35.87	20.82	24.31
Operating Income	-51.81	-64.30	-64.30	-51.51	-32.66	-21.80	-18.75
Other Income/Expense
Interest Income	-1.15	3.36	3.36	3.85	0.05	0.00	0.33
Interest Expense	1.15	0.00	-0.30	-1.40	0.00	0.93	0.00
Other Income/Expense	-0.89	3.28	3.28	-1.46	-0.95	-1.22	-0.18
Income
Income Before Tax	-52.70	-61.02	-61.02	-49.12	-33.61	-23.01	-21.36
Income Tax Expense	0.00	0.00	-	0.00	0.00	0.00	0.00
Net Income	-52.96	-61.02	-61.02	-49.12	-33.61	-23.01	-21.36
Net Income - Continuous Operations	-52.70	-61.02	-61.02	-49.12	-33.61	-23.01	-21.36
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-51.48	-60.72	-63.99	-51.22	-33.39	-21.91	-18.62
EBIT	-51.81	-	-64.30	-51.51	-32.66	-22.09	-18.75
Depreciation & Amortization	0.33	0.31	0.31	0.29	0.22	0.18	0.14
Earnings Per Share
Basic EPS	-1.00	-2.00	-2.00	-1.00	-1.00	-	-11.00
Diluted EPS	-1.00	-2.00	-2.00	-1.00	-1.00	-	-11.00
Basic Shares Outstanding	47.75	36.82	36.82	33.23	25.47	20.45	2.01
Diluted Shares Outstanding	47.75	36.82	36.82	33.23	25.47	20.45	2.01

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Orchestra BioMed Holdings Financial Statements

What was Orchestra BioMed Holdings's revenue in fiscal 2025?

Orchestra BioMed Holdings reported revenue of $33.48M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 1169.2% from $2.64M a year earlier.

Is Orchestra BioMed Holdings profitable?

No. Orchestra BioMed Holdings reported a net loss of $52.95M in fiscal 2025. In fiscal 2024 it lost $61.02M.

What is Orchestra BioMed Holdings's operating margin?

Orchestra BioMed Holdings's operating income was −$51.81M on revenue of $33.48M in fiscal 2025, an operating margin of -154.7%, compared with -2437.5% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition